Our project aims to develop an improved DPD inhibitor which will enhance immunotherapy efficacy in MSI-H metastatic CRC. This innovative approach leverage for the first time the targeting of a key metabolic pathway to modulate the immune cell activity in the tumor microenvironment. Our drug holds the potential to overcome resistance and expand immunotherapy efficacy to novel indications in CRC.
